Cargando…

A randomized, double-blind, placebo-controlled, phase II dose-finding study of the short acting β(1)-blocker, landiolol hydrochloride, in patients with suspected ischemic cardiac disease

The purpose of this study was to compare the safety and efficacy of the short-acting β(1)-receptor blocker, landiolol hydrochloride (0.06 and 0.125-mg/kg), to placebo during coronary computed tomography angiography (CTA) in a phase 2 dose-finding study. A total of 183 patients suspected of having is...

Descripción completa

Detalles Bibliográficos
Autores principales: Jinzaki, Masahiro, Hirano, Masaharu, Hara, Kazuhiro, Suzuki, Takahiko, Yamashina, Akira, Ikari, Yuji, Iino, Misako, Yamaguchi, Takuhiro, Kuribayashi, Sachio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722440/
https://www.ncbi.nlm.nih.gov/pubmed/23784548
http://dx.doi.org/10.1007/s10554-013-0253-3
Descripción
Sumario:The purpose of this study was to compare the safety and efficacy of the short-acting β(1)-receptor blocker, landiolol hydrochloride (0.06 and 0.125-mg/kg), to placebo during coronary computed tomography angiography (CTA) in a phase 2 dose-finding study. A total of 183 patients suspected of having ischemic cardiac disease and scheduled to undergo an invasive coronary angiography were randomized to groups treated with landiolol hydrochloride (0.06 or 0.125-mg/kg) or placebo. The heart rate, safety, and the performance of coronary diagnosis using landiolol hydrochloride were evaluated in a multicenter, double-blind, randomized, parallel study. The patients’ heart rates during the coronary CTA were 67.6 ± 8.7 and 62.6 ± 7.8 beats/min in the 0.06 and 0.125-mg/kg landiolol hydrochloride groups, respectively, both of which were significantly lower than the heat rate of 73.7 ± 11.8 beats/min in the placebo group (P = 0.003 and P < 0.001, respectively). No adverse events or reactions occurred at an incidence of 5 % or greater, confirming the safety of landiolol hydrochloride. The proportion of correctly classified patients was significantly higher in the 0.125-mg/kg landiolol hydrochloride group than in the placebo group (73.6 vs. 50.0 %). Landiolol hydrochloride at doses of 0.06 and 0.125-mg/kg significantly decreased the heart rate compared with a placebo. The present findings suggest that landiolol hydrochloride is safe and useful at a dose of 0.125-mg/kg to improve coronary diagnostic performance during coronary CTA.